Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.
Disparities
Genetic testing
Health equity
Prostate cancer
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
received:
24
04
2024
accepted:
06
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-engagement of Black males in PCA GT, limiting the benefit of precision therapy and tailored cancer screening despite longstanding awareness of these disparities. To address these critical disparities, the Socioecological Model (SEM) was employed to develop comprehensive recommendations to overcome barriers and implement equitable strategies to engage Black males in PCA GT. Clinical/research experts, national organization leaders, and community stakeholders spanning multiple regions in US and Africa participated in developing a framework for equity in PCA GT grounded in the SEM. A novel mixed-methods approach was employed to generate key areas to be addressed and informed statements for consensus consideration utilizing the modified Delphi model. Statements achieving strong consensus (> =75% agreement) were included in final equity frameworks addressing clinical/community engagement and research engagement. All societal levels of the SEM (interpersonal, institutional, community, and policy/advocacy) must deliver information about PCA GT to Black males that address benefits/limitations, clinical impact, hereditary cancer implications, with acknowledgment of mistrust (mean scores [MS] 4.57-5.00). Interpersonal strategies for information delivery included engagement of family/friends/peers/Black role models to improve education/awareness and overcome mistrust (MS 4.65-5.00). Institutional strategies included diversifying clinical, research, and educational programs and integrating community liaisons into healthcare institutions (MS 4.57-5.00). Community strategies included partnerships with healthcare institutions and visibility of healthcare providers/researchers at community events (MS 4.65-4.91). Policy/advocacy included improving partnerships between advocacy and healthcare/community organizations while protecting patient benefits (MS 4.57-5.00). Media strategies were endorsed for the first time at every level (MS 4.56-5.00). The SEM-based equity frameworks proposed provide the first multidisciplinary strategies dedicated to increase engagement of Black males in PCA GT, which are critical to reduce disparities in PCA-mortality through informing tailored screening, targeted therapy, and cascade testing in families.
Sections du résumé
BACKGROUND
BACKGROUND
Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is the significant under-engagement of Black males in PCA GT, limiting the benefit of precision therapy and tailored cancer screening despite longstanding awareness of these disparities. To address these critical disparities, the Socioecological Model (SEM) was employed to develop comprehensive recommendations to overcome barriers and implement equitable strategies to engage Black males in PCA GT.
METHODS
METHODS
Clinical/research experts, national organization leaders, and community stakeholders spanning multiple regions in US and Africa participated in developing a framework for equity in PCA GT grounded in the SEM. A novel mixed-methods approach was employed to generate key areas to be addressed and informed statements for consensus consideration utilizing the modified Delphi model. Statements achieving strong consensus (> =75% agreement) were included in final equity frameworks addressing clinical/community engagement and research engagement.
RESULTS
RESULTS
All societal levels of the SEM (interpersonal, institutional, community, and policy/advocacy) must deliver information about PCA GT to Black males that address benefits/limitations, clinical impact, hereditary cancer implications, with acknowledgment of mistrust (mean scores [MS] 4.57-5.00). Interpersonal strategies for information delivery included engagement of family/friends/peers/Black role models to improve education/awareness and overcome mistrust (MS 4.65-5.00). Institutional strategies included diversifying clinical, research, and educational programs and integrating community liaisons into healthcare institutions (MS 4.57-5.00). Community strategies included partnerships with healthcare institutions and visibility of healthcare providers/researchers at community events (MS 4.65-4.91). Policy/advocacy included improving partnerships between advocacy and healthcare/community organizations while protecting patient benefits (MS 4.57-5.00). Media strategies were endorsed for the first time at every level (MS 4.56-5.00).
CONCLUSION
CONCLUSIONS
The SEM-based equity frameworks proposed provide the first multidisciplinary strategies dedicated to increase engagement of Black males in PCA GT, which are critical to reduce disparities in PCA-mortality through informing tailored screening, targeted therapy, and cascade testing in families.
Identifiants
pubmed: 39289635
doi: 10.1186/s12889-024-20008-8
pii: 10.1186/s12889-024-20008-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2533Informations de copyright
© 2024. The Author(s).
Références
Cancer Facts and Figures. American Cancer Society. Available at: https://www.cancer.org . Accessed 1 Mar 2024.
National Comprehensive Cancer Network. Prostate Cancer. Version 3.2024. [Accessed March 1 2024] Available at: www.nccn.org .
National Comprehensive Cancer Network. Prostate Cancer Early Detection. Version 2.2024. [Accessed March 1, 2024] Available at: www.nccn.org .
National Cancer Institute: genetics of prostate cancer (PDQ®). Available at: https://www.cancer.gov . Accessed 1 March 2024.
National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. Available at: www.nccn.org . Accessed 1 Mar 2024.
Hann KEJ, Freeman M, Fraser L, et al. Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. BMC Public Health. 2017;17:503. https://doi.org/10.1186/s12889-017-4375-8 .
doi: 10.1186/s12889-017-4375-8
pubmed: 28545429
pmcid: 5445407
Rogers CR, Rovito MJ, Hussein M, et al. Attitudes toward genomic testing and prostate cancer research among black men. Am J Prev Med. 2018;55(5 Suppl 1):S103-111.
doi: 10.1016/j.amepre.2018.05.028
pubmed: 30670195
pmcid: 6352989
Davis TC, Arnold CL, Mills G, Miele L. A qualitative study exploring barriers and facilitators of enrolling underrepresented populations in clinical trials and biobanking. Front Cell Dev Biol. 2019;7: 74.
doi: 10.3389/fcell.2019.00074
pubmed: 31114788
pmcid: 6502895
Khan A, Rogers CR, Kennedy CD, Lopez A, Jeter J. Genetic evaluation for hereditary cancer syndromes among African americans: a critical review. Oncologist. 2022;27(4):285–91.
doi: 10.1093/oncolo/oyab082
pubmed: 35380723
pmcid: 8982373
Giri VN, Shimada A, Leader AE. Predictors of population awareness of cancer genetic tests: implications for enhancing equity in engaging in cancer prevention and precision medicine. J Clin Oncol – Precision Oncol. 2021;5:1699–708.
doi: 10.1200/PO.21.00231
Sallis JF, Owen N, Fisher EB. Ecological models of health behavior. In: Glanz K, Rimer BK, Viswanath K, editors. Health Behavior and Health Education. 4th ed. San Francisco: Wiley; 2008. p. 465–85.
Pritchard CC, et al. Inherited DNA- repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.
doi: 10.1056/NEJMoa1603144
pubmed: 27433846
pmcid: 4986616
Giri VN, et al. Inherited mutations in males undergoing multigene panel testing for prostate cancer — emerging implications for personalized prostate cancer genetic evaluation. J Clin Oncol Precis Oncol. 2017;1:1–17.
Nicolosi P, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523–8.
doi: 10.1001/jamaoncol.2018.6760
pubmed: 30730552
pmcid: 6459112
Pritzlaff M, Tian Y, Reineke P, et al. Diagnosing hereditary cancer predisposition in men with prostate cancer. Genet Med. 2020;22(9):1517–23.
doi: 10.1038/s41436-020-0830-5
pubmed: 32439974
pmcid: 7462744
de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.
doi: 10.1056/NEJMoa1911440
pubmed: 32343890
Abida W, et al. Rucaparib in men with metastatic castration- resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.20.01035 .
doi: 10.1200/JCO.20.01035
pubmed: 32795228
pmcid: 7655021
Smith MR, Scher HI, Sandhu S, GALAHAD investigators. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23(3):362–73.
doi: 10.1016/S1470-2045(21)00757-9
pubmed: 35131040
pmcid: 9361481
Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR. Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):403–10.
doi: 10.1038/s41391-021-00469-3
pubmed: 34775478
Petrovics G, Price DK, Lou H, et al. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer Prostatic Dis. 2019;22(3):406–10.
doi: 10.1038/s41391-018-0114-1
pubmed: 30542053
Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. Ethnic disparities among men with prostate cancer undergoing germline testing. Urol Oncol. 2020;38(3):80.
doi: 10.1016/j.urolonc.2019.09.010
Sartor O, Yang S, Ledet E, Moses M, Nicolosi P. Inherited DNA-repair gene mutations in African American men with prostate cancer. Oncotarget. 2020;11(4):440–2.
doi: 10.18632/oncotarget.27456
pubmed: 32064047
pmcid: 6996909
Patel AV, Jacobs EJ, Dudas DM, et al. The American Cancer Society’s Cancer Prevention Study 3 (CPS-3): recruitment, study design, and baseline characteristics. Cancer. 2017;123(11):2014–24.
doi: 10.1002/cncr.30561
pubmed: 28171707
Patel AV, Deubler E, Teras LR, et al. Key risk factors for the relative and absolute 5-year risk of cancer to enhance cancer screening and prevention. Cancer. 2022;128(19):3502–15.
doi: 10.1002/cncr.34396
pubmed: 35920750
Connecticut Catchment Area Profile. Center for Community Engagement and Health Equity at Yale Cancer Center. Accessed 22 Oct. 2023. https://www.yalecancercenter.org/research/cehe/
Guerra C, Pressman A, Hurley P, et al. Increasing racial and ethnic equity, diversity, and inclusion in cancer treatment trials: evaluation of an ASCO-Association of Community Cancer centers site self-assessment. JCO Oncol Pract. 2023;19(4):e581-8.
doi: 10.1200/OP.22.00560
pubmed: 36630663
pmcid: 10101254
Oyer RA, Hurley P, Boehmer L, et al. Increasing racial and ethnic diversity in Cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. J Clin Oncol. 2022;40(19):2163–71.
doi: 10.1200/JCO.22.00754
pubmed: 35588469
Fu J, Fu C, Wang R, Geynisman DM, Ghatalia P, Lynch SM, Harrison SR, Tagai EK, Ragin C. Current status and future direction to address disparities in diversity, equity, and inclusion in prostate cancer care. Curr Oncol Rep. 2023;25:1–10. https://doi.org/10.1007/s11912-023-01399-0 .
doi: 10.1007/s11912-023-01399-0
Reopell L, Nolan TS, Gray DM II, Williams A, Brewer LC, Bryant AL, et al. Community engagement and clinical trial diversity: navigating barriers and co-designing solutions—a report from the health equity through diversity seminar series. PLoS One. 2023;18(2):e0281940. https://doi.org/10.1371/journal.pone.0281940 .
doi: 10.1371/journal.pone.0281940
pubmed: 36795792
pmcid: 9934412
Wilkins CH. Effective engagement requires trust and being trustworthy. Med Care. 2018;56(10 Suppl 1):S6-8. https://doi.org/10.1097/MLR.0000000000000953 . PMID: 30015725; PMCID: PMC6143205.
doi: 10.1097/MLR.0000000000000953
pubmed: 30015725
pmcid: 6143205
Garrick O, Mesa R, Ferris A, Kim ES, Mitchell E, Brawley OW, Carpten J, Carter KD, Coney J, Winn R, Monroe S, Sandoval F, Perez E, Williams M, Grove E, Highsmith Q, Richie N, Begelman SM, Collins AS, Freedman J, Gonzales MS, Wilson G. Advancing inclusive research: establishing collaborative strategies to improve diversity in clinical trials. Ethn Dis. 2022;32(1):61–8. https://doi.org/10.18865/ed.32.1.61 . PMID: 35106045; PMCID: PMC8785867.
doi: 10.18865/ed.32.1.61
pubmed: 35106045
pmcid: 8785867
Tucker-Seeley RD. Financial toxicity: a barrier to achieving health equity in cancer care. J Am Coll Radiol. 2023;20(1):37–9.
doi: 10.1016/j.jacr.2022.12.004
pubmed: 36503172
ZERO Prostate Cancer: Patient support hotline ZERO 360. Available at https://zerocancer.org/help-and-support/ZERO360 . Accessed 22 Oct 2023.
Murphy AB, Abern MR, Liu L, et al. Impact of a genomic test on treatment decision in a predominantly African American population with favorable-risk prostate cancer: a randomized trial. J Clin Oncol. 2021;39(15):1660–70.
doi: 10.1200/JCO.20.02997
pubmed: 33835822
pmcid: 8148420
Goulbourne T, Yanovitzky I. The communication infrastructure as a social determinant of health: implications for health policymaking and practice. Milbank Q. 2021;99(1):24–40.
doi: 10.1111/1468-0009.12496
pubmed: 33528043
pmcid: 7984672
Lumpkins CY, Nelson R, Twizele Z, et al. Communicating risk and the landscape of cancer prevention - an exploratory study that examines perceptions of cancer-related genetic counseling and testing among African americans and latinos in the Midwest. J Community Genet. 2023;14(2):121–33.
doi: 10.1007/s12687-022-00629-5
pubmed: 36930422
pmcid: 10021032
Coleman C, Birk S, DeVoe J. Health literacy and systemic racism-using clear communication to reduce health care inequities. JAMA Intern Med. 2023;183(8):753–4.
doi: 10.1001/jamainternmed.2023.2558
pubmed: 37358860
McGuirt J, Sokol RL, Tang PY, Vines AI, Walker JS, Fisher EB. Peer support opportunities across the cancer care continuum: a systematic scoping review of recent peer-reviewed literature. Support Care Cancer. 2019;27(1):97–108.
doi: 10.1007/s00520-018-4479-4
pubmed: 30293093
Flora PK, Bender JL, Miller AS, et al. A core competency framework for prostate cancer peer navigation. Support Care Cancer. 2020;28(6):2605–14.
doi: 10.1007/s00520-019-05059-7
pubmed: 31616997
King AJL, Evans M, Moore THM, Paterson C, Sharp D, Persad R, Huntley A. Prostate cancer and supportive care: a systematic review and qualitative synthesis of men’s experiences and unmet needs. Euro J Cancer Care. 2015;24:618–34.
doi: 10.1111/ecc.12286
Montgomery B, Rettig M, Kasten J, Muralidhar S, Myrie K, Ramoni R. The precision oncology program for cancer of the prostate (POPCaP) network: a Veterans Affairs/Prostate Cancer Foundation Collaboration. Fed Pract. 2020;37(Suppl 4):S48-53.
pubmed: 32908353
pmcid: 7473728
Hellwig LD, Krokosky A, Vargason A, Turner C. Genetic counseling considerations for military beneficiaries. Mil Med. 2021;187(Suppl 1):36–9.
doi: 10.1093/milmed/usab007
pubmed: 34967403
pmcid: 8717321
Smith ML, Railey E. Research advocacy network: advancing patient-focused research. J Oncol Pract. 2007;3(3):158. https://doi.org/10.1200/JOP.0735002 .
doi: 10.1200/JOP.0735002
pubmed: 29455606
pmcid: 2793784
Rocque GB, Andrews C, Lawhon VM, et al. Oncologist-reported barriers and facilitators to enrolling patients in optimization trials that test less intense cancer treatment. JCO Oncol Pract. 2023;19(2):e263-73.
doi: 10.1200/OP.22.00472
pubmed: 36473142
Lachance J, Berens AJ, Hansen MEB, Teng AK, Tishkoff SA, Rebbeck TR. Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent. Cancer Res. 2018;78(9):2432–43.
doi: 10.1158/0008-5472.CAN-17-1550
pubmed: 29438991
pmcid: 5932264
Rebbeck TR, Devesa SS, Chang BL, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013;2013: 560857. https://doi.org/10.1155/2013/560857 .
doi: 10.1155/2013/560857
pubmed: 23476788
pmcid: 3583061
Patton MQ. Qualitative Research & Evaluation Methods. Thousand Oaks, CA, USA: Sage; 2002.
Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Early detection (CAPS) onsortium. Gut. 2020;69:7–17.
doi: 10.1136/gutjnl-2019-319352
pubmed: 31672839
Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019. J Clin Oncol. 2020;38(24):2798–811.
doi: 10.1200/JCO.20.00046
pubmed: 32516092
pmcid: 7430215
Peterson EB, Chou WS, Gaysynsky A, Krakow M, Elrick A, Khoury MJ, Kaphingst KA. Communication of cancer-related genetic and genomic information: a landscape analysis of reviews. Transl Behav Med. 2018;8(1):59–70.
doi: 10.1093/tbm/ibx063
pubmed: 29385592
pmcid: 6065548
Loeb S, Massey P, Leader AE, et al. Gaps in public awareness about BRCA and genetic testing in prostate cancer: social media landscape analysis. JMIR Cancer. 2021;7(3): e27063. https://doi.org/10.2196/27063 .
doi: 10.2196/27063
pubmed: 34542414
pmcid: 8550715